Skip to main content

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health
Currently Open As of Jan 7, 2026
Application Opens Nov 22, 2024
Deadline Nov 19, 2026
Geography Not specified

Next Steps

Visit Official Grant Page → ← Back to All Grants Report Issue

Share This Grant

Data Source & Verification

Source: www.grants.gov
Last Verified: Jan 7, 2026, 7:15 PM
Important: Always verify current details directly on the official grant website before applying.